Pfizer, Evotec Team Up to Combat Tissue Fibrosis

Pharmaceutical giant Pfizer is joining forces with Evotec in a four-year deal to combat tissue fibrosis.

The research partnership will make use of Germany-based Evotec’s drug discovery platform and Pfizer’s wide network of technologies, drug development and marketing expertise.

The companies will search for innovative treatments to address multi-organ fibrosis, a critical condition with few effective options to reduce life-threatening scarring that can lead to organ failure.

Financial terms of the deal were not disclosed, but include an upfront payment and achievement-based payments related to development and sales milestones.

Evotec, whose focus has been in on kidney fibrosis, views the move as a growth opportunity. Pfizer sees Evotec as well-positioned to create cutting-edge discoveries in several areas of fibrosis. — Victoria Pelham